Tech Company Financing Transactions
Axoltis Pharma Funding Round
MAIF Avenir participated in a $21 million Series A capital raise for Axoltis Pharma. The financing was announced by the company on 12/2/2025.
Transaction Overview
Company Name
Announced On
12/2/2025
Transaction Type
Venture Equity
Amount
$21,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to pursue the development of NX210c, its lead drug candidate, currently in phase 2 clinical trials in patients with ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig's disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Clermont-Ferrand, Undisclosed
France
Clermont-Ferrand, Undisclosed
France
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Our vocation is to develop first-in-class innovative drugs to treat patients with degenerative or traumatic neurological disorders with high unmet medical needs. Our ambition is to improve the recovery of the functionality and the quality of life of patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yann Godfrin
Browse more venture capital transactions:
Prev: 12/1/2025: Sokin venture capital transaction
Next: 12/2/2025: Ascentra Labs venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs